Last reviewed · How we verify
placebo, fostamatinib
Fostamatinib is a spleen tyrosine kinase (Syk) inhibitor.
Fostamatinib is a spleen tyrosine kinase (Syk) inhibitor. Used for Chronic immune thrombocytopenia (cITP).
At a glance
| Generic name | placebo, fostamatinib |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Syk inhibitor |
| Target | Syk |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Fostamatinib works by selectively inhibiting Syk, a key enzyme involved in the activation of immune cells. This inhibition leads to a reduction in the production of pro-inflammatory cytokines and mediators, resulting in anti-inflammatory effects.
Approved indications
- Chronic immune thrombocytopenia (cITP)
Common side effects
- Diarrhea
- Nausea
- Headache
- Fatigue
Key clinical trials
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies (PHASE1)
- Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults (PHASE2)
- A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 (PHASE3)
- International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response (PHASE2, PHASE3)
- Novel Experimental COVID-19 Therapies Affecting Host Response (PHASE2, PHASE3)
- Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects (PHASE3)
- A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA (PHASE3)
- Fostamatinib for Hospitalized Adults With COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |